BPI-23314

BPI-23314 is an orally bioavailable small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, including BRD2, BRD3, BRD4, and BRDT. Developed by Beta Pharma, it functions as an epigenetic modulator by competitively binding to the acetyl-lysine binding pockets of BET bromodomains. This action prevents the recruitment of BET proteins to chromatin, thereby suppressing the expression of key oncogenic drivers such as MYC and BCL2. BPI-23314 is primarily being investigated for the treatment of hematologic malignancies, specifically relapsed or refractory acute myeloid leukemia (AML), and has also shown potential in advanced solid tumors. Clinical trials are currently evaluating its safety, tolerability, and preliminary efficacy as a monotherapy.